Candel Therapeutics (CADL) appoints Nicoletta Loggia, PhD, RPh to board effective June 7, 2023

Candel Therapeutics, Inc.

Board size increased from 9 to 10; Dr. Loggia appointed as Class III director with term expiring at 2024 annual meeting.
She receives option for 28,480 shares vesting over 3 years plus standard non-employee director cash compensation.
Dr. Loggia is CTO at Orchard Therapeutics, formerly Global Head of Cell & Gene Therapies at Novartis, with 20+ years experience.
Appointment adds manufacturing expertise as company approaches phase 3 pivotal readout in localized prostate cancer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nicoletta Loggia

Class III Director

CADL · Candel Therapeutics, Inc.

Effective: 2023-06-07
Filed: June 8, 2023, 7:59 PM ET

unanimously appointed Nicoletta Loggia, Ph.D., R.Ph., to fill the newly created vacancy on the Board, effective June 7, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Nicoletta Loggia was appointed as Class III Director at Candel Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

unanimously appointed Nicoletta Loggia, Ph.D., R.Ph., to fill the newly created vacancy on the Board, effective June 7, 2023.

View on SEC.gov

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-026913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.